Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -70.74% is 89% above its 5-year average of -656.24%, near the high end of its 5-year range (-2049.93%–52.68%).
92.58% above its 12-month average of -952.78%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -1368.07%.
EBITDA MARGIN
-70.74%
EBITDA MARGIN AVG TTM
-952.78%
EBITDA MARGIN AVG 3Y
-1025.38%
EBITDA MARGIN AVG 5Y
-656.24%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+92.58%
CURRENT VS 3Y AVG
+93.10%
CURRENT VS 5Y AVG
+89.22%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
IDEAYA Biosciences, Inc.
Market Cap
$3.53B
EBITDA Margin
-70.74%
TTM Avg
-952.78%
3Y Avg
-1025.38%
5Y Avg
-656.24%
Market Cap
$3.62B
EBITDA Margin
-1.38%
TTM Avg
-8.27%
3Y Avg
-15.09%
5Y Avg
-16.30%
Market Cap
$3.42B
EBITDA Margin
10.88%
TTM Avg
18.32%
3Y Avg
-3.89%
5Y Avg
-19.05%
Market Cap
$3.11B
EBITDA Margin
-54.45%
TTM Avg
-179.51%
3Y Avg
-231.98%
5Y Avg
-287.87%
Market Cap
$3.10B
EBITDA Margin
-1.82%
TTM Avg
-32.91%
3Y Avg
-2154.05%
5Y Avg
-2154.05%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| IDEAYA Biosciences, Inc. (IDYA) | $3.53B | -70.74% | -952.78% | -1025.38% | -656.24% |
| Celcuity Inc. (CELC)vs › | $3.49B | N/A | N/A | N/A | N/A |
| CareDx, Inc (CDNA)vs › | $3.58B | -1.23% | 8.45% | -16.90% | -13.40% |
| iRhythm Technologies, Inc. (IRTC)vs › | $3.62B | -1.38% | -8.27% | -15.09% | -16.30% |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.42B | 10.88% | 18.32% | -3.89% | -19.05% |
| Denali Therapeutics Inc. (DNLI)vs › | $3.11B | -54.45% | -179.51% | -231.98% | -287.87% |
| Enliven Therapeutics, Inc. (ELVN)vs › | $3.11B | N/A | N/A | N/A | N/A |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $3.10B | -1.82% | -32.91% | -2154.05% | -2154.05% |
| ICU Medical, Inc. (ICUI)vs › | $3.98B | 14.57% | 8.24% | 9.01% | 11.36% |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.04B | -359.19% | -174.35% | -417.41% | -1450.57% |
Gross Margin
-43.9%
EBITDA Margin
-70.7%
Operating Margin
-72.8%
Net Margin
-74.8%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -1368.07% |
| 2026-03-31 | -1637.21% |
| 2025-12-31 | -858.52% |
| 2025-09-30 | 52.68% |
| 2024-12-31 | -2049.93% |
| 2023-12-31 | -1042.39% |
| 2023-09-30 | -404.83% |
| 2023-06-30 | -894.78% |
| 2023-03-31 | -321.31% |
| 2022-12-31 | -643.61% |
| 2022-09-30 | 5.34% |
| 2022-06-30 | -363.95% |
| 2022-03-31 | -121.10% |
| 2021-12-31 | -605.60% |
| 2021-09-30 | -124.92% |
| 2021-06-30 | -121.64% |
| 2021-03-31 | -120.78% |
| 2020-12-31 | -46.53% |
| 2020-09-30 | -52.37% |
